Harmony Biosciences Reports Continued Momentum for Pitolisant
Harmony Biosciences Holdings Inc reported business updates for the quarter ended March 31, noting continued momentum in its commercial business for Wakix (pitolisant), as well as in the advancement of its clinical development programs for pitolisant for the treatment of idiopathic hypersomnia. Wakix, a first-in-class medication approved by the US Food and Drug Administration (FDA)…